
10/07/2025
Just Announced: In partnership with Gilead Sciences, The Global Fund has secured access to lenacapavir, a breakthrough, long-acting injectable HIV prevention drug, for low- and middle-income countries.
This marks the first time in history that an HIV prevention product will be introduced in low- and middle-income countries at the same time as in high-income countries – a milestone for global health equity.
“This is not just a scientific breakthrough – it’s a turning point for HIV/AIDS. For the first time, we have a tool that can fundamentally change the trajectory of the HIV epidemic – but only if we get it to the people who need it most.” – Peter Sands, Executive Director
https://www.theglobalfund.org/en/news/2025/2025-07-09-global-fund-secures-access-breakthrough-hiv-prevention-drug-lenacapavir/